Preclinical IPF and Pulmonary Fibrosis Models
Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease characterized by impaired gas exchange, restrictive lung mechanics, extracellular matrix deposition, and progressive loss of functional lung architecture.
IPS Therapeutique offers mouse and rat models of bleomycin-induced pulmonary fibrosis to support the preclinical evaluation of anti-fibrotic, anti-inflammatory, lung-protective, and disease-modifying therapeutics.
The bleomycin model remains one of the most widely used tools in pulmonary fibrosis research, but it is not a stand-alone predictor of clinical efficacy. Its value depends on rigorous experimental execution, appropriate timing of treatment, integration of functional and histological endpoints, and careful interpretation of results in the context of the drug’s mechanism of action.
At IPS Therapeutique, pulmonary fibrosis studies are designed to provide decision-supporting data, not simply a positive or negative model response.
